Global News and Digital Insights
for the Healthcare Industry

Novartis’ Scemblix becomes the first approved STAMP inhibitor after snagging European nod

After securing FDA’s approval last year, Novartis’ drug Scemblix for a type of chronic myeloid leukaemia has bagged a regulatory European nod as well. The drug asciminib will be branded under the name Scemblix and has received the European Commission’s OK for patients suffering from chronic myeloid leukaemia (CML), a tumour that targets bone marrow. The standard treatment for CML has its faults: either the cancer grows resistant to the small molecule drugs, or the side effects eventually cause patients to cease taking tyrosine kinases blocking drugs altogether. Scemblix offers a slightly altered treatment, acting on the approach called “specifically targeting ABL myristoyl pocket” (STAMP). This drug is the first approved STAMP inhibitor for CML.

Read More from MedCityNews